Chargement en cours...
Phase I/II Study of Temozolomide Plus Nimustine Chemotherapy for Recurrent Malignant Gliomas: Kyoto Neuro-oncology Group
The objective of this phase I/II study was to examine the efficacy and toxicity profile of temozolomide (TMZ) plus nimustine (ACNU). Patients who had received a standard radiotherapy with one or two previous chemo-regimens were enrolled. In phase I, the maximum-tolerated dose (MTD) by TMZ (150 mg/m(...
Enregistré dans:
| Publié dans: | Neurol Med Chir (Tokyo) |
|---|---|
| Auteurs principaux: | , , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
The Japan Neurosurgical Society
2017
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5243161/ https://ncbi.nlm.nih.gov/pubmed/27725524 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2176/nmc.oa.2016-0162 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|